Angiotech Pharmaceuticals, Inc.

Interim clinical trial results demonstrate safety and efficacy of coronary stent

Published in FDA Law Weekly, November 24th, 2005

Angiotech Pharmaceuticals, Inc. (ANP) corporate partner, Boston Scientific (BSC), reported interim results from the independent, multicenter STENT registry that further demonstrate the efficacy and safety of Boston Scientific's Taxus Express(2) paclitaxel-eluting coronary stent system among real-world patients with blocked coronary arteries.

An analysis of data on patients who have completed 9 months of follow-up to date revealed a numerical trend favoring the Taxus stent over Johnson & Johnson's Cypher sirolimus-eluting stent system in reducing major adverse cardiovascular events (MACE) and target vessel revascularization (TVR). The interim results were presented at...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of FDA Law Weekly

Source: FDA Law Weekly (2005-11-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry